Sep 2026· Journal of Chemical Information and Modeling· Vol 66, pp. 12740 - 12771· 0 citations· 95 references
TL;DR
This study employed an integrated ligand-based virtual screening pipeline to identify potential CASP4 inhibitors from the DrugBank database, leveraging docking-score prioritization, SMILES-derived ChemBERTa embeddings, and key physicochemical descriptors to systematically prioritize repurposed DrugBank compounds for CASP4-targeted Alzheimer’s disease therapy.
Abstract
This study employed an integrated ligand-based virtual screening pipeline to identify potential CASP4 inhibitors from the DrugBank database, leveraging docking-score prioritization, SMILES-derived ChemBERTa embeddings, and key physicochemical descriptors. Building on this foundation, the workflow incorporated virtual screening, cheminformatics modeling, PK–PD evaluation, molecular docking, molecular dynamics simulations, and MM/PBSA free-energy analysis to systematically prioritize repurposed DrugBank compounds for CASP4-targeted Alzheimer’s disease therapy. A Random Forest classifier trained on the hybrid ChemBERTa physicochemical feature set distinguished active from inactive compounds with ∼95% accuracy (ROC–AUC = 0.73) and achieved a ∼3.5-fold enrichment of active compounds among the top-ranked hits, while a companion Random Forest regressor, trained on the experimental pIC50 values of active compounds, ranked candidates by predicted potency. In addition, integrated cheminformatics modeling, PK–PD analysis, and molecular docking further narrowed the selection to the top five candidate compounds: DB00519, DB01068, DB06202, DB08882, and DB05316. Finally, MD simulations and MM/PBSA calculations established clear thermodynamic support for DB05316 and DB00519, whose binding free energies (−21.4 and −20.9 kcal/mol, respectively) exceeded even the reference compound donepezil, highlighting them as the most promising CASP4 inhibitors. Overall, this workflow provides an efficient and robust strategy for prioritizing repositioned DrugBank compounds as potential CASP4 inhibitors against Alzheimer’s disease.
This work developed a compound prioritization strategy that utilizes sampled docked poses from complementary docking approaches into multiple conformations of the target protein to train two multilayer perceptron (MLP) models, and found that a combination of scoring and prediction metrics enriches for hit compounds acr...
A. Chang-Gonzalez, Alexis N. Campbell, Eric W. Bell et al.· Journal of Chemical Informat...· 0 citations
AIM
Janus kinase 3 (JAK3) is a key therapeutic target in autoimmune and inflammatory diseases. This study aimed to identify novel JAK3 inhibitors using an integrated machine learning and structure-based computational approach.
MATERIALS AND METHODS
Random Forest Regression model was developed from 4,336 JAK3 inhibito...
Muhammad Yasir, Jinyoung Park, Eun-Taek Han et al.· Future Medicinal Chemistry· 1 citation
Quantitative structure-activity relationship (QSAR) modelling is central to computer-aided drug discovery, yet many existing QSAR tools operate as isolated descriptor-generation or single-algorithm utilities that require programming expertise and manual transfer of outputs into separate docking and simulation programs....
M. Islam, S. Bhowmick, Sonali Chikhale· Computational biology and ch...· 0 citations
Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) prediction plays a central role in modern computer-aided drug discovery by enabling early evaluation of pharmacokinetic behaviour and safety liabilities. This tutorial presents a reproducible computational workflow for large-scale ADMET profiling usi...
Festus O. Ogungbemiro, Jane O. Anebi, Felix O. Okunlola et al.· Journal of Cheminformatics· 0 citations
Objective: This study aimed to establish a pathway-driven computational drug discovery framework integrating machine learning, target prioritization, virtual screening, molecular dynamics (MD) simulations, and in vitro evaluation to identify natural small molecules with potential anti-rheumatoid arthritis (RA) activity...
Ji-Jia Sun, Yue-Zhen Wang, Hong Ye et al.· Pharmaceuticals· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.